

ANSWER 9 OF 11 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY05743 Protein DGENE

TITLE: Identifying agonists and antagonists of tumor necrosis factor related receptors TR1, TR3 and TR5, and of ligand TL3, useful for treatment of cancer, AIDS, Alzheimer's disease, bone disease etc

INVENTOR: McDonnell P C; Young P R; Zou J

PATENT ASSIGNEE: (SMIK)SMITHKLINE BEECHAM CORP.

PATENT INFO: EP 911633 A1 19990428 23p

APPLICATION INFO: EP 1998-203332 19981002

PRIORITY INFO: US 1997-61334 19971008

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1999-246560 [21]

AN AAY05743 Protein DGENE

AB The present sequence represents tumour necrosis factor receptor (TNFR) TR31, also known as DR3, **Apo3**, WSL-1 or LARD. The invention relates to TNFR related polypeptides TR1, TR3 and TR5 (see AAY05742-44) and their ligand TL3 (see AAY05745). TR1, TR3, TR5 and TL3 are used in claimed methods of identifying agonists and antagonists, i.e. compounds that bind to the receptors or ligand, and which activate (agonist) or inhibit activation of (antagonists) TR1, TR3, TR5 or TL3. A screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes etc. for TR1, TR3, TR5 or TL3 polypeptides is provided. The agonists and antagonists are useful for treatment of chronic and acute inflammation, arthritis, septicaemia, autoimmune disease e.g. inflammatory bowel disease, psoriasis, transplant rejection, **graft versus host disease**, infection, stroke, ischaemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, cancer (e.g. lymphoproliferative disorders), atherosclerosis, Alzheimer's disease, etc., caused by imbalance of TR1, TR3, TR5 or TL3.

ANSWER 18 OF 23 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAY45043 Protein DGENE

TITLE: Novel apoptotic proteins Apop1, Apop2 and Apop3 and recombinant nucleic acids encoding them for use in screening modulators which is useful for diagnosis and treatment of diseases -

INVENTOR: Luo Y; Huang B C B; Shen M; Yu P W

PATENT ASSIGNEE: (RIGE-N)RIGEL PHARM INC.

PATENT INFO: WO 2000007545 A2 20000217

64p

APPLICATION INFO: WO 1999-US17776 19990806

PRIORITY INFO: US 1998-95587 19980806

US 1998-95590 19980806

US 1998-99486 19980908

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-205547 [18]

AN AAY45043 Protein DGENE

AB The patent discloses the use of novel apoptotic proteins and related molecules involved in apoptosis modulation. Expression vectors comprising the Apop DNA can be used to transform host cells. Apop DNA can be **administered** as DNA vaccines. Apop proteins are used to make polyclonal and monoclonal **antibodies** for use in immunotherapy. The proteins are useful in treating apoptosis-mediated disorders including cancer, autoimmune disorders, sustained viral infection, inappropriate cell loss and degenerative disorders. Drug candidates that affect Apop bioactivity are identified by screening. The present sequence is a C-terminal truncation mutant of Apop3 (1-436) protein also known as RIP3 (receptor-interacting protein). This mutant has dramatically reduced binding affinity for RIP and fails to induce apoptosis. Apop3 (1-436) inhibited TNFalpha-induced caspase activation. **Apo3** is associated with the TNFalpha (tumour necrosis factor) signalling complex and TNF induced NF (nuclear factor) kappaB transcription factor activation. Note: The present sequence is not

| | | | | | | | | |
|----------|-------------------|-------------|--------------------|-----------|----------|----------|-------|-------|
| CBT | PubMed | | | | | | | |
| PubMed | Nucleotide | Protein | Genome | Structure | PopSet | Taxonomy | OMIM | Books |
| Search | PubMed | for | tweak | and | antibody | Go | Clear | |
| Limits | Preview/Index | History | Clipboard | Details | | | | |
| Display | Summary | Sort | Save | Text | Clip Add | Order | | |
| Show: 20 | Items 41-51 of 51 | Page 3 of 3 | Select page: 1 2 3 | | | | | |

Entrez
PubMed

☐ **41: Hamel G.**

Related Articles

Strategy as revolution.

Harv Bus Rev. 1996 Jul-Aug;74(4):69-82.

PMID: 10158475 [PubMed - indexed for MEDLINE]

PubMed
Services

☐ **42: Cherpitel CJ.**

Related Articles

Screening for alcohol problems in the emergency room: a rapid alcohol problems screen.

Drug Alcohol Depend. 1995 Dec;40(2):133-7.

PMID: 8745135 [PubMed - indexed for MEDLINE]

☐ **43: Cherpitel CJ.**

Related Articles

Analysis of cut points for screening instruments for alcohol problems in the emergency room.

J Stud Alcohol. 1995 Nov;56(6):695-700.

PMID: 8558901 [PubMed - indexed for MEDLINE]

Related
Resources

☐ **44: Murray CW, Clark DE, Byrne DG.**

Related Articles

PRO_LIGAND: an approach to de novo molecular design. 6. Flexible fitting in the design of peptides.

J Comput Aided Mol Des. 1995 Oct;9(5):381-95.

PMID: 8594156 [PubMed - indexed for MEDLINE]

☐ **45: Allen JP, Maisto SA, Connors GJ.**

Related Articles

Self-report screening tests for alcohol problems in primary care.

Arch Intern Med. 1995 Sep 11;155(16):1726-30. Review.

PMID: 7654105 [PubMed - indexed for MEDLINE]

☐ **46: Cherpitel CJ.**

Related Articles

Screening for alcohol problems in the emergency department.

Ann Emerg Med. 1995 Aug;26(2):158-66.

PMID: 7618778 [PubMed - indexed for MEDLINE]

☐ **47: Cherpitel CJ, Clark WB.**

Related Articles

Ethnic differences in performance of screening instruments for identifying harmful drinking and alcohol dependence in the emergency room.

Alcohol Clin Exp Res. 1995 Jun;19(3):628-34.

PMID: 7573785 [PubMed - indexed for MEDLINE]

- Display Summary ▼ Sort ▼ Save Text Clip Add Order
 Show: 20 ▼ Items 41-51 of 51 Page 3 of 3 Select page: 1 2 3

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer